Biopharmaceutical Fermentation Market size is expected to reach USD 9,839.6 million in 2021 and poised to grow at a Significant CAGR of 4.7% within the forecast period of 2022-2028. The technique of incubation microbes in a contained tank or fermenter under controlled settings of aeration, agitation, temperature, and pH is known as a biopharmaceutical fermentation system. Fermentation is the only method for making chemical APIs that rely entirely on microbes like antibiotics or secondary metabolites produced by fungi that act as anti-infectious or anti-cancer drugs or lipid A produced by gram-negative bacteria that act as adjuvants. Such organic molecules can be created from their building blocks using a multi-step synthesis process which would be highly time-consuming and costly if produced in the lab while maintaining the chiral and stereospecific characteristics. The COVID-19 epidemic had a negative impact on the biopharmaceutical fermentation market’s growth in its early stages, but this market is anticipated to acquire momentum because of the pressing need to create a vaccine and other biological products. Numerous significant developments were produced in the field of pharmaceutical R&D as a result of COVID-19. In order to safeguard people worldwide from this virus, scientists and researchers are attempting to uncover diagnostics, therapies, and novel vaccinations. The biopharmaceutical fermentation systems market has grown as a result of these developments. For example, the Journal of Industrial Integration and Management reports that in 2021, due to recent advancements in the R&D field and technological solutions based on biosensors, these biosensors will be used to monitor the real-time activity of bioreactors for the determination of various physiological and pharmacological parameters as well as to supervise synthetic specifications in the manufacturing operation (in bioreactors). One of the principal elements propelling the development of the biopharmaceutical fermentation systems market is the rising need for biotechnology-based advanced products, such as monoclonal antibodies and antibody derivatives, vaccines, and monoclonal antibodies, as well as rising research and development to generate biomedical substances.
Key Developments in the Biopharmaceutical Fermentation Market:
In February 2021, the commercial production, formulation, and downstream processing of CureVac’s CVnCoV COVID-19 candidate vaccine have been disclosed by Rentschler Biopharma, a contract development and manufacturing organization (CDMO) with headquarters in Germany. In a similar vein, Bayer also declared that it would produce 160 million doses of CVnCoV in 2022.
In December 2020, Thermo Fischer Scientific started to grow in North America and other regions to produce several essential drugs, vaccines, and treatments for commercial sale. 15 (commercial Good Manufacturing Practices) cGMP supporting a variety of manufacturing capabilities were added as a result of this growth.